PEDIATRIC PHARMACOLOGY

Pharmacology and Therapeutics: Principles to Practice

Volumn , Issue , 2008, Pages 239-249

  Neville, Kathleen A ^a   Blake, Michael J ^b   Reed, Michael D ^c,d   Kearns, Gregory L ^a,e  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b Ottumwa Pediatrics   (United States)

^c AKRON CHILDREN'S HOSPITAL   (United States)

^d NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84974820776     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3291-5.50021-4     Document Type: Chapter

References (77)

1. S Halpern (1988) The social dynamic of professionalism. American Pediatrics Berkeley, CA: University of California Press 52.
2. GL Kearns, SM Abdel-Rahman, SW Alander, et al. (2003) Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 349(12), 1157-1167.
3. R Loebstein and G Koren (1998) Clinical pharmacology and therapeutic drug monitoring in neonates and children. Pediatr Rev 19(12), 423-428.
4. WA Ritschel and GL Kearns (2004) Pediatric pharmacokinetics. WA Ritschel, GL Kearns (Eds) Handbook of Basic Pharmacokinetics Including Clinical Applications Washington, DC: American Pharmacists Association 227-239.
5. M Agunod, N Yamaguchi, R Lopez, et al. (1969) Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am J Dig Dis 14(6), 400-414.
6. P Rodbro, PA Krasilnikoff and PM Christiansen (1967) Parietal cell secretory function in early childhood. Scand J Gastroenterol 2(3), 209-213.
7. M Gupta and YW Brans (1978) Gastric retention in neonates. Pediatrics 62(1), 26-29.
8. PI Ittmann, R Amarnath and CL Berseth (1992) Maturation of antroduodenal motor activity in preterm and term infants. Dig Dis Sci 37(1), 14-19.
9. G Heimann (1980) Enteral absorption and bioavailability in children in relation to age. Eur J Clin Pharmacol 18(1), 43-50.
10. LT Weaver, S Austin and TJ Cole (1991) Small intestinal length: a factor essential for gut adaptation. Gut 32(11), 1321-1323.
11. RJ Grand, JB Watkins and FM Torti (1976) Development of the human gastrointestinal tract. A review. Gastroenterology 70(5 pt 1), 790-810.
12. M Martinussen, AM Brubakk, DT Linker, et al. (1994) Mesenteric blood flow velocity and its relation to circulatory adaptation during the first week of life in healthy term infants. Pediatr Res 36(3), 334-339.
13. M Martinussen, AM Brubakk, T Vik and AC Yao (1996) Mesenteric blood flow velocity and its relation to transitional circulatory adaptation in appropriate for gestational age preterm infants. Pediatr Res 39(2), 275-280.
14. TD Yanowitz, AC Yao, KD Pettigrew, et al. (1999) Postnatal hemodynamic changes in very-low-birthweight infants. J Appl Physiol 87(1), 370-380.
15. JR Poley, JC Dower, CA Owen Jr and GB Stickler (1964) Bile acids in infants and children. J Lab Clin Med 63 838-846.
16. FJ Suchy, WF Balistreri, JE Heubi, et al. (1981) Physiologic cholestasis: elevation of the primary serum bile acid concentrations in normal infants. Gastroenterology 80(5 pt 1), 1037-1041.
17. SD Hall, KE Thummel, PB Watkins, et al. (1999) Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 27(2), 161-166.
18. MR Stahlberg, E Hietanen and M Maki (1988) Mucosal biotransformation rates in the small intestine of children. Gut 29(8), 1058-1063.
19. JP Gibbs, CA Liacouras, RN Baldassano and JT Slattery (1999) Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos 27(12), 1466-1469.
20. M Fakhoury, C Litalien, Y Medard, et al. (2005) Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 33(11), 1603-1607.
21. C Di Lorenzo, AF Flores and PE Hyman (1995) Age-related changes in colon motility. J Pediatr 127(4), 593-596.
22. KP Coulthard, HW Nielson, M Schroder, et al. (1998) Relative bioavailability and plasma paracetamol profiles of Panadol suppositories in children. J Paediatr Child Health 34(5), 425-431.
23. LS Stratchunsky, AD Nazarov, AA Firsov and NA Petrachenkova (1991) Age dependence of erythromycin rectal bioavailability in children. Eur J Drug Metab Pharmacokinet 321-323. spec no 3
24. RA van Lingen, JT Deinum, JM Quak, et al. (1999) Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates. Arch Dis Child Fetal Neonatal Ed 80(1), F59-F63.
25. M Amato, P Huppi, M Isenschmid and H Schneider (1992) Developmental aspects of percutaneous caffeine absorption in premature infants. Am J Perinatol 9(5–6), 431-434.
26. DP West, S Worobec and LM Solomon (1981) Pharmacology and toxicology of infant skin. J Invest Dermatol 76(3), 147-150.
27. N Rutter (1987) Percutaneous drug absorption in the newborn: hazards and uses. Clin Perinatol 14(4), 911-930.
28. JW Fluhr, S Pfisterer and M Gloor (2000) Direct comparison of skin physiology in children and adults with bioengineering methods. Pediatr Dermatol 17(6), 436-439.
29. FA Okah, RR Wickett, WL Pickens and SB Hoath (1995) Surface electrical capacitance as a noninvasive bedside measure of epidermal barrier maturation in the newborn infant. Pediatrics 96(4 pt 1), 688-692.
30. DJ Greenblatt and J Koch-Weser (1976) Intramuscular injection of drugs. N Engl J Med 295(10), 542-546.
31. MR Carry, SP Ringel and JM Starcevich (1986) Distribution of capillaries in normal and diseased human skeletal muscle. Muscle Nerve 9(5), 445-454.
32. DA Kafetzis, CA Sinaniotis, CJ Papadatos and J Kosmidis (1979) Pharmacokinetics of amikacin in infants and pre-school children. Acta Paediatr Scand 68(3), 419-422.
33. KT Sheng, NN Huang and V Promadhattavedi (1964) Serum concentrations of cephalothin in infants and children and placental transmission of the antibiotic. Antimicrob Agents Chemother (Bethesda) 10 200-206.
34. MJ Painter, C Pippenger, C Wasterlain, et al. (1981) Phenobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution. Neurology 31(9), 1107-1112.
35. C Tsai, M Ahdab-Barmada, MJ Daood and JF Watchko (2001) P-Glycoprotein expression in the developing human central nervous system: cellular and tissue localization. Pediatr Res 47 436A.
36. RN Hines and DG McCarver (2002) The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 300(2), 355-360.
37. DG McCarver and RN Hines (2002) The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 300(2), 361-366.
38. R Hartley, M Green, MW Quinn, et al. (1994) Development of morphine glucuronidation in premature neonates. Biol Neonate 66(1), 1-9.
39. DA Barrett, DP Barker, N Rutter, et al. (1996) Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. Br J Clin Pharmacol 41(6), 531-537.
40. E Saarenmaa, PJ Neuvonen, P Rosenberg and V Fellman (2000) Morphine clearance and effects in newborn infants in relation to gestational age. Clin Pharmacol Ther 68(2), 160-166.
41. CS Scott, KW Riggs, EW Ling, et al. (1999) Morphine pharmacokinetics and pain assessment in premature newborns. J Pediatr 135(4), 423-429.
42. RP Miller, RJ Roberts and LJ Fischer (1976) Acetaminophen elimination kinetics in neonates, children, and adults. Clin Pharmacol Ther 19(3), 284-294.
43. EV Capparelli, JA Englund, JD Connor, et al. (2003) Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol 43(2), 133-140.
44. J Robillard, E Guillery and J Petershack (1999) Renal function during fetal life. TM Barratt, ED Avner, WE Harmon (Eds) Pediatric Nephrology Baltimore: Lippincott Williams & Wilkins 21-37.
45. BS Arant Jr (1978) Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr 92(5), 705-712.
46. JN van den Anker, RC Schoemaker, WC Hop, et al. (1995) Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. Clin Pharmacol Ther 58(6), 650-659.
47. MW Davies and DW Cartwright (1998) Gentamicin dosage intervals in neonates: longer dosage interval—less toxicity. J Paediatr Child Health 34(6), 577-580.
48. JN van den Anker, WC Hop, R de Groot, et al. (1994) Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant. Pediatr Res 36(5), 578-581.
49. J Marshall, A Rodarte, J Blumer, et al. (2000) Pediatric pharmacodynamics of midazolam oral syrup. Pediatric Pharmacology Research Unit Network. J Clin Pharmacol 40(6), 578-589.
50. JD Marshall and GL Kearns (1999) Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther 66(1), 66-75.
51. H Takahashi, S Ishikawa, S Nomoto, et al. (2000) Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 68(5), 541-555.
52. NN deWildt, GL Kearns, SD Sie, et al. (2003) Pharmacodynamics of intravenous and oral midazolam in preterm infants. Clin Drug Invest 23 27-38.
53. CH Pui, D Campana and WE Evans (2001) Childhood acute lymphoblastic leukaemia—current status and future perspectives. Lancet Oncol 2(10), 597-607.
54. ES Silverman, SB Liggett, EW Gelfand, et al. (2001) The pharmacogenetics of asthma: a candidate gene approach. Pharmacogenomics J 1(1), 27-37.
55. JS Leeder (2001) Ontogeny of drug-metabolizing enzymes and its influence on the pathogenesis of adverse drug reactions in children. Curr Ther Res 62 900-912.
56. GL Kearns (2000) Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol 106(3 suppl), S128-S138.
57. J Alcorn and PJ McNamara (2002) Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet 41(13), 1077-1094.
58. PH Rheinstein (1994) Avoiding problems with liquid medications and dosing devices. Am Fam Physician 50(8), 1771-1772.
59. SS Shah, M Hall, DM Goodman, et al. (2007) Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med 161(3), 282-290.
60. R Roberts, W Rodriguez, D Murphy and T Crescenzi (2003) Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 290(7), 905-911.
61. P Impicciatore, I Choonara, A Clarkson, et al. (2001) Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 52(1), 77-83.
62. BC Carleton, MA Smith, MN Gelin and SC Heathcote (2007) Paediatric adverse drug reaction reporting: understanding and future directions. Can J Clin Pharmacol 14(1), e45-e57.
63. DS Budnitz, DA Pollock, KN Weidenbach, et al. (2006) National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296(15), 1858-1866.
64. MJ Blake, A Gaedigk, RE Pearce, et al. (2007) Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 81(4), 510-516.
65. RM Ward and R Kauffman (2007) Future of pediatric therapeutics: reauthorization of BPCA and PREA. Clin Pharmacol Ther 81(4), 477-479.
66. GL Kearns, WA Ritschel, JT Wilson and SP Spielberg (2007) Clinical pharmacology: a discipline called to action for maternal and child health. Clin Pharmacol Ther 81(4), 463-468.
67. SM Abdel-Rahman, MD Reed, TG Wells and GL Kearns (2007) Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls. Clin Pharmacol Ther 81(4), 483-494.
68. JT Gilman and P Gal (1992) Pharmacokinetic and pharmacodynamic data collection in children and neonates. A quiet frontier. Clin Pharmacokinet 23(1), 1-9.
69. B Friis-Hansen (1983) Water distribution in the foetus and newborn infant. Acta Paediatr Scand Suppl 305 7-11.
70. WS Young and PS Lietman (1978) Chloramphenicol glucuronyl transferase: assay, ontogeny and inducibility. J Pharmacol Exp Ther 204(1), 203-211.
71. JM Treluyer, E Jacqz-Aigrain, F Alvarez and T Cresteil (1991) Expression of CYP2D6 in developing human liver. Eur J Biochem 202(2), 583-588.
72. MT Kinirons, D O'Shea, RB Kim, et al. (1999) Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 66(3), 224-231.
73. S Pynnonen, M Sillanpaa, H Frey and E Iisalo (1977) Carbamazepine and its 10,11-epoxide in children and adults with epilepsy. Eur J Clin Pharmacol 11(2), 129-133.
74. JV Aranda, JM Collinge, R Zinman and G Watters (1979) Maturation of caffeine elimination in infancy. Arch Dis Child 54(12), 946-949.
75. DJ Murry, WR Crom, WE Reddick, et al. (1995) Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 23(10), 1110-1116.
76. PL Morselli (1983) Development of physiological variables important for drug kinetics. PL Morselli, CE Pippenger, JK Penry (Eds) Antiepileptic Drug Therapy in Pediatrics New York: Raven 1-12.
77. O Linderkamp, HT Versmold, KP Riegel and K Betke (1977) Estimation and prediction of blood volume in infants and children. Eur J Pediatr 125 227-234.